2024 SABCS Meeting Magazine - 15

DECEMBER 13 (ALL TIMES ARE IN CENTRAL STANDARD TIME)
Friday
12:00 - 12:55 p.m.
Rapid Fire 3
HALL 1
Moderator: Peter Fasching,
University Hospital Erlangen and
Comprehensive Cancer Center
Erlangen-EMN, Germany
* RF3-01: TBCRC 056:
A phase II study of
neoadjuvant niraparib with
dostarlimab for patients
with BRCA- or PALB2mutated
breast cancer:
Results from the ER+/
HER2- cohort.
Erica Mayer, Dana-Farber
Cancer Institute, Boston,
Massachusetts
* RF3-02: Efficacy of adjuvant
avelumab by PD-L1, tumor
infiltrating lymphocytes
and residual cancer burden
in high-risk triple negative
breast cancer: secondary
and exploratory endpoints
of the phase III A-BRAVE
trial.
Maria Vittoria Dieci, University
of Padua, Padua, Italy
* RF3-03: Nivolumab +
Ipilimumab (NIVO+IPI)
compared to capecitabine
for triple-negative breast
cancer patients with
residual disease after
neoadjuvant chemotherapy
- Final results of
BreastImmune-03, a
multicenter randomized
open-label phase II trial.
Olivier Trédan, Centre Lèon
Bèrard, Lyon, France
* RF3-04: NRG-BR004: A
Randomized, Double-blind,
Phase III Trial of Taxane/
Trastuzumab/Pertuzumab
with Atezolizumab or
Placebo in First-line HER2positive
Metastatic Breast
Cancer.
Vicente Valero, MD Anderson
Cancer Center, Houston, Texas
* RF3-05: A Phase 2
Study of Neoadjuvant
HER2-targeted Therapy
+/- Immunotherapy with
Pembrolizumab (neoHIP).
Heather McArthur, UT
Southwestern Medical Center,
Dallas, Texas
* RF3-06: Mepitel Film
for the Reduction of
Radiation Dermatitis
in Post-mastectomy
Radiation Therapy: Results
from Alliance A221803:
A Multicenter Phase III
Randomized Clinical Trial
Kimberly Corbin, Mayo Clinic,
Rochester, Minnesota
* RF3-07: ROSCO:Response
to Optimal Selection of
neoadjuvant Chemotherapy
in Operable breast cancer:
A randomised phase
III, stratified biomarker
trial of neoadjuvant
5-Fluorouracil, Epirubicin
& Cyclophosphamide
vs Docetaxel &
Cyclophosphamide
chemotherapy.
Daniel Rea, University of
Birmingham, Birmingham,
United Kingdom
12:30 - 2:00 p.m.
Poster Session 5
HALLS 2-3
12:30 - 2:00 p.m.
The Pathologists
Conundrum: IHC Testing in
Breast Cancer
ROOM 221 ABC
Moderator: David Rimm, Yale
School of Medicine, New Haven,
Connecticut
* A Brief History of IHC in
Breast Cancer and ASCO
CAP Guidelines
Kim Allison, Stanford
University/Stanford Cancer
Institute, Palo Alto, California
* The FDA's Perspective: What
is Required for a Companion
Diagnostic Test
Reena Philips, FDA,
Gaithersburg, Maryland
* Evaluation of the accuracy
of Reading IHC
Giuseppe Viale, European
Institute of Oncology, Milan,
Italy
* Evaluation of the Accuracy
of Digital Measuring
Andrew Beck, Path AI, Boston,
Massachusetts
12:30 - 1:45 p.m.
Risk Reduction and Early
Detection: New Directions in
Breast Cancer Prevention
STARS AT NIGHT 3-4
Moderator: Gretchen Gierach,
National Cancer Institute,
Bethesda, Maryland
* Prevention Vaccines: Where
Are We Now and Where Are
We Going?
Olivera Finn, University
of Pittsburgh, Pittsburgh,
Pennsylvania
* Can We Use Biomarkers to
Implement Prevention?
Seema Khan, Feinberg School
of Medicine of Northwestern
University, Chicago, Illinois
* From Bench to Clinical Trial:
A New Target for Breast
Cancer Prevention
Geoff Lindeman, Walter and
Eliza Hall Institute of Medical
Research, Parkville, Australia
* Panel Discussion
2:00 - 2:50 p.m.
Debate: All Patients Should
be Offered Universal
Germline Genetic Testing
STARS AT NIGHT 3-4
Moderator: Andrew Tutt, The
Institute of Cancer Research,
London, United Kingdom
* Opening Remarks and
Polling
* Debate For
Allison Kurian, Stanford
University, Palo Alto,
California
* Debate Against
Raymond Kim, UHN Princess
Margaret Cancer Centre,
Toronto, Canada
* Closing Remarks and Polling
3:00 - 5:00 p.m.
Year in Review
STARS AT NIGHT 1-2
Moderators: Carlos Arteaga, UT
Southwestern Medical Center,
Dallas, Texas; and Virginia
Kaklamani, UT Health Mays Cancer
Center, San Antonio, Texas
* Basic Science
Neil Vasan, Columbia
University, New York, New York
* Translational Science
Updates
Pedram Razavi, Memorial
Sloan Kettering Cancer
Center, New York, New York
* Early Breast Cancer
Updates
Janice Tsang, University of
Hong Kong, Hong Kong, China
* Advanced Breast Cancer
Updates
Michael Danso, Virginia
Oncology Associates, Norfolk,
Virginia
5:00 - 5:30 p.m.
Reception Break
5:30 - 7:00 p.m.
View from the Trenches
STARS AT NIGHT 1-2
Moderator: Joyce O'Shaughnessy,
Baylor-Sammons Cancer Center,
Dallas, Texas
Patient Advocate: Stacey Tinianov,
Santa Cruz, California
* Medical Oncology
Cristina Saura, Vall d'Hebron
University Hospital and
Vall d'Hebron Institute of
Oncology (VHIO), Barcelona,
Spain
Antonio Wolff, Johns Hopkins
Medicine, Baltimore, Maryland
* Radiation Oncology
Atif Khan, Memorial Sloan
Kettering Cancer Center, New
York, New York
* Surgical Oncology
Alastair Thompson, Baylor
College of Medicine, Houston,
Texas
December 10-13, 2024 | San Antonio, Texas
15
2024 SABCS Meeting Magazine

Table of Contents for the Digital Edition of 2024 SABCS Meeting Magazine
